Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | HTR1D | P28221 | 6/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | HTR7 | P34969 | 6/20 | 0.51 |
| ▸ | HTR2B | P41595 | 6/20 | 0.51 |
| ▸ | HTR5A | P47898 | 6/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5454205 | 0.90 | ADRA1D (0.55) | HTR1AHTR1DHTR2CHTR7HTR2B | |
| SCHEMBL5451215 | 0.89 | ADRA1D (0.45) | HTR1AHTR1DHTR2CHTR7HTR2B | |
| SCHEMBL5457456 | 0.88 | ADRA1D (0.49) | HTR1AHTR7HTR2AADRA1DADRA1A | |
| SCHEMBL14412214 | 0.87 | DRD3 (0.50) | HTR2AADRA1DADRA1AADRA1BCNR2 | |
| SCHEMBL5446521 | 0.87 | HTR1A (0.55) | HTR1AHTR1DHTR2CHTR7HTR2B | |
| SCHEMBL5451251 | 0.85 | CNR2 (0.50) | ADRA1DCNR2 | |
| SCHEMBL5456434 | 0.85 | CNR2 (0.51) | CNR2 | |
| SCHEMBL5448948 | 0.84 | CNR2 (0.47) | ADRA1DADRA1ACNR2 | |
| SCHEMBL5318855 | 0.84 | CNR2 (0.47) | HTR1AHTR7HTR2AADRA1DCNR2 | |
| SCHEMBL5454223 | 0.83 | CNR2 (0.48) | ADRA1DCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HTR1A 417/4885HTR1D 628/4885HTR2C 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.